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Abstract In sclerosing epithelioid fibrosarcoma (SEF), a
rare variant of low-grade fibrosarcoma, treatment results
and therapeutic options are poorly characterized. We sys-
tematically analyzed the data of all 89 patients (43 female,
46 male; mean age, 47 years [range, 14–87 years]) reported
in the literature concerning clinical presentation, histopa-
thology, differential diagnosis, treatment, survival rates,
and prognosis, and we present an additional case. Infor-
mation detailing treatment, disease control, and followup
was available in 60 (67%), 75 (84%), and 68 patients (76%),
respectively. Case history was variable with one-third of
patients reporting a painful, enlarging mass. Ten patients
(13%) presented with metastases, 23 (31%) had metastases
develop after diagnosis, and 28 (37%) had local recurrence.
Low cellularity, mild pleomorphy, and sclerotic hyaline
matrix of SEF suggest a benign clinical behavior, and cell
morphology allows for the wide differential diagnosis of
benign, pseudosarcomatous, and malignant proliferations.
In addition to surgery, 11 patients (15%) had chemotherapy,
22 (29%) had postoperative radiation therapy, and three
(4%) had a combination of both. Twenty-three patients
(34%) died from their disease after a mean of 46 months, 24
(35%) were alive with disease, and 20 (31%) were alive
without evidence of disease. Patients with SEF of the head
and neck had the worst prognosis.
Level of Evidence: Level III, prognostic study. See the
Guidelines for Authors for a complete description of levels
of evidence.
Introduction
Sclerosing epithelioid fibrosarcoma is a rare and poorly
recognized but distinct variant of fibrosarcoma (ICD-O
code 88 10/3). Since it was originally published in 1995 by
Meis-Kindblom et al. in a series of 25 patients [36], 25
reports on 89 patients with a main focus on histopathologic
and immunohistochemical features have been reported
[1, 2, 4–7, 9, 10, 12–16, 18, 22, 23, 25, 29–32, 36, 40, 42,
43]. These reports suggest SEF is characterized histopa-
thologically by low-grade tumor features: round or oval
cells typically arranged in a cord- or nest-like distribution
with a collagen background almost effacing the neoplastic
cells. Mitotic figures are either scant or absent, and necrosis
is uncommon. Sclerosing epithelioid fibrosarcoma is
characterized by rearrangement of 10p11 [25, 40] and
amplification of 12q13 and 12q15, including the HMGIC
gene, a transcriptional activator [16]. Together with low-
grade fibromyxoid sarcoma (FMS) and hyalinizing spindle
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cell tumor with giant rosettes (HSCTGR) [3], SEF belongs
to the family of fibrosing fibrosarcomas [44, 45]. Each of
these tumors has distinctive clinical features; they share in
common histologic components suggesting a close rela-
tionship [3, 20, 21, 42, 43].
The response of SEF to treatment has not yet been fully
characterized. Furthermore, the current low-grade classifi-
cation might be misleading because it disregards the full
malignant potential of SEF. The resulting lack of famil-
iarity of treating physicians with SEF might lead to
misinterpretation of this rare entity. Thus, the malignant
potential of SEF might be underestimated. The potential
consequence of this is inadequate therapy leading to an
unfavorable treatment result.
Consequently, we systematically reviewed the literature
to highlight the following questions: Is there a typical
clinical presentation of SEF (patient history, tumor size and
location, distant tumor manifestation, and rate of metasta-
sis)? What are the histopathologic features of SEF and
what differential diagnoses arise? How were patients with
SEF treated and how does this therapy influence overall,
disease-free survival and prognosis? Does distant disease
depend on tumor size? How do location of the primary
tumor, local treatment, and gender influence the prognosis?
Materials and Methods
We performed a systematic review of all SEF studies and
case presentations published until December 22, 2007. All
publications were derived from NCBI-PubMed (www.
pubmed.gov) and Embase (www.embase.com) using the
search term sclerosing epithelioid fibrosarcoma. Together,
this yielded 34 articles, of which 25 were primarily about
SEF. We included all these 25 studies in the current review
and analyzed them in detail. The remaining nine studies
concern articles about fibromyxoid sarcoma [41] or soft
tissue tumor pathology [24, 37], low-grade fibrosarcoma
not otherwise specified [28], rhabdomyosarcoma [20], deep
fibromatosis [8], or mention SEF only marginally [21, 27,
33]. Thus, we did not include these studies in our review.
Since 1995, 89 patients (not including our patient) were
evaluated in these 25 studies regarding tumor characteris-
tics, treatment, and clinical outcome [1, 2, 4–7, 9, 10, 12–
16, 18, 22, 23, 25, 29–32, 36, 40, 42, 43]. Information
detailing treatment, disease control, and followup was
available in 60 (67%), 75 (84%), and 68 patients (76%),
respectively (Supplemental Website Material; a supple-
mental table is available with the online version of CORR).
Including our case, tumors were 8 cm on average and the
mean patient age was 47 years (range, 14–87 years)
(Table 1). The mean duration between first signs or
symptoms and diagnosis was 33 months on average (range,
1 month–13 years). Sixty patients underwent surgery,
which included biopsy only (n = 2 [3%]); not further
specified resection/unspecified surgery (n = 25 [42%]);
amputation (n = 5 [8%]); and wide (n = 21 [35%]),
marginal, and intralesional excisions (n = 7 [12%]). In
eight patients, information regarding age was not provided.
Sixteen of 82 patients (19%) were younger than 30 years at
diagnosis, 30 patients (37%) were 30 to 50 years old, and
36 patients (44%) were older than 50 years. Study quality
was judged according to the levels of evidence based on the
US Preventive Services Task Force for ranking evidence
regarding the effectiveness of treatments or screening as
presented by Clinical Orthopaedics and Related Research
(http://www.editorialmanager.com/corr/).
We tested the influence of gender on prognosis of SEF
using the Wilcoxon rank sum test. We used SPSS for
Windows (SPSS, Chicago, IL). A value of p \ 0.05 was
considered statistically significant.
Case Report
A 32-year-old woman presented with an 18-month history
of increasing swelling at her right distal lateral forearm,
which initially was painless. Conventional radiographs
Table 1. Patients’ characteristics
Characteristic Number of patients
in whom information
was provided per
study population
Mean Quality
Gender 90/90 44 females, 46 males
Age 82/90 47 years (range, 14–87 years)
History (months) 23/90 33 years (range, 1 month–13 years)
Size (cm) 78/90 8.3 years (range, 1–25 years)
Surgery 60/90 Biopsy only (n = 2); not further specified
resection/unspecified surgery (n = 25);
amputation (n = 5); wide excision (n = 21),
marginal and intralesional excision (n = 7)
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showed a punched-out osteolytic lesion surrounded by a
sclerotic rim at the ulna (Fig. 1). Magnetic resonance
imaging revealed a 5 9 1.5-cm tumor and some edema of
the bone marrow (Fig. 2).
We performed a core needle biopsy and after estab-
lishing the diagnosis, performed complete gross resection
with positive microscopic resection margins. Because of
tumor infiltration, the extensor carpi ulnaris muscle and
parts of the adjacent muscles were removed. Subsequently,
we used a tricortical autologous bone graft from the iliac
crest for reconstruction. A 3.5-mm low-contact dynamic
compression plate was used to fix the bone graft and to
provide stability to the ulna (Fig. 3).
Histologically, there was a sharply demarcated tumor
mass in the direct vicinity of the periosteum with infiltra-
tion of the cortical bone. The tumor tissue consisted of
highly collagenized extracellular matrix with a low density
of cells arranged in loose bundles. Most of the cells were
elongated with a spindle-shaped nucleus and abundant
eosinophilic cytoplasm (Fig. 3A). Focally, particularly at
the periphery of the tumor, there were somewhat more
cellular areas with plump, epithelioid cells of variable size
and individual large, pleomorphic nuclei with prominent
nucleoli (Fig. 3B). We detected no mitotic figures or areas
of necrosis. Immunohistochemically, no reactivity was
detected to any of the tested epithelial, myogenic, or neural
markers (actin, desmin, myogenin, S-100, cytokeratin,
beta-catenin, CD 31, CD 34, CD 99, CD 117, EMA, bcl-2,
MDM-2, MIB-1) with sole positivity for the relatively
unspecific, mesenchymal intermediate filament vimentin
(Fig. 3C). Thus, we established the diagnosis of a SEF on
morphologic criteria.
Subsequently, we administered adjuvant radiation ther-
apy (66 Gy, 1.8 Gy per session). No systemic treatment
was given.
Two years postoperatively, imaging studies, including
computed tomography of the chest and MRI of the right
forearm, confirmed no local tumor and no evidence of
systemic disease.
Results
Based on our literature review, the clinical behavior of SEF
was generally aggressive with recurrence after resection in
27 of the 90 patients (30%) at the various times of reported
followups. One patient had persistent disease and in 15
patients (17%), information regarding recurrence was not
provided by the respective authors. Tumor size at diagnosis
averaged 8.3 cm (range, 1–25 cm). Most patients had a
Fig. 1 (A) Anteroposterior and (B) lateral radiographs show a
punched-out osteolytic lesion surrounded by a sclerotic rim at the
middiaphysis of the right ulna.
Fig. 2 An MRI scan of the right forearm shows a 5 9 1.5-cm tumor
extending into the soft tissues and slight bone marrow edema.
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variable case history with one-third reporting a painful and
enlarging mass, mostly a deep muscular lesion associated
with the adjacent fascia or periosteum. The most frequent
tumor sites were the lower extremities/limb girdle (n = 35
[39%]; average tumor size, 9.37 cm) and trunk (n = 19
[21%]; average tumor size, 7.60 cm) followed by the upper
extremities (n = 13 [14.5%]; average tumor size,
7.65 cm), the head and neck (n = 13 [14.5%]; average
tumor size, 6.69 cm), and abdominal/inguinal (n = 10
[11%]; average tumor size, 9.39 cm). Overall, 75 of 90
patients (83%) were reported to have distant disease at a
mean of 36 months after diagnosis. Ten of 37 patients
(27%) presented with metastases at the time of the primary
diagnosis. The most frequent site of distant tumor mani-
festation was the lung (n = 26 [70%]) followed by osseous
lesions to multiple bones (n = 15 [41%]) and to the pleura/
chest wall (n = 4 [11%]). Two patients had metastases to
the scalp (5%). Lymphatic spread, metastases to the breast
and to the liver were reported in one patient (3%). Fourteen
patients (38%) had metastases to multiple sites. None of
the patients with bone involvement had a bone tumor
elsewhere.
In SEF, the deceptively low cellularity, mild pleomor-
phy, and the densely sclerotic hyaline matrix may suggest a
benign clinical behavior. Cell morphology allows for the
wide differential diagnosis of benign, pseudosarcomatous,
and malignant proliferations. The typical morphologic
features of sarcomas such as pronounced pleomorphy,
infiltrative growth pattern, necrosis, and mitotic activity
may be inconspicuous or even absent. These include nod-
ular fasciitis, myositis ossificans, fibromatosis, hyalinizing
leiomyoma, fibrous histiocytoma, lobular or signet ring cell
carcinoma, sclerosing lymphoma, granulocytic sarcoma,
ossifying fibromyxoid tumor, synovial sarcoma, or small
cell osteosarcoma.
One patient received preoperative radiation therapy
(50 Gy). Twenty-one patients (37%) received postopera-
tive radiation therapy (50.4–70.2 Gy) and 10 of 22 patients
(45%) received indicated radiation therapy doses. Ten of
56 patients (18%) received chemotherapy, and three
patients underwent combined radiation therapy and che-
motherapy. Twenty-seven patients (36%) experienced local
recurrence after a mean of 36 months (range, 2–
132 months) after diagnosis and treatment. In each age
subgroup, there were 50% to 60% of patients who were
alive with disease or who had died of disease (DOD).
Distant disease seemed independent of tumor size (nine
of 23 tumors [39%] with 5 cm or less, 15 of 33 tumors
[45%] with 5–10 cm, and 10 of 22 with 10 cm [45%] or
greater metastasized). However, no patient with a primary
tumor of 5 cm or less initially presented with metastases.
Tumors of patients with metastasis at diagnosis (n = 10)
were larger (11.3 cm; range, 7.5–17 cm) than tumors
that subsequently metastasized (n = 23; 7.7 cm; range,
2.5–19.5 cm) and tumors of patients without metastasis
(n = 43; 8 cm; range, 1–25 cm). Forty-six percent (17 of
37 patients) of patients with metastases experienced local
recurrence, and 63% of patients with local recurrence (17
of 27 patients) had distant metastases develop. Seven of 11
patients who underwent systemic chemotherapy had
systemic disease develop.
With respect to location, patients with SEF of the head
and neck had the worst prognosis with six of 13 patients
(46%) DOD followed by SEF of the upper extremities (five
of 13 [38%]) and the trunk (five of 19 [26%]). The influ-
ence of local treatment could not be assessed adequately
because of incompletely reported data regarding surgical
procedures, resection status, followup, and missing criteria
for radiotherapy.
Fig. 3A–C (A) Histologically, the tumor consists of extensive areas
with high collagen content and scarce mesenchymal cells (Stain,
hematoxylin & eosin; original magnification, 9400). (B) At the tumor
periphery, there are areas with higher cellularity and more pro-
nounced cell atypia (arrow) (Stain, hematoxylin & eosin; original
magnification, 9200). (C) The tumor cells are immunohistochemi-
cally positive for the mesenchymal marker vimentin (Dako, Baar,
Switzerland; antibody dilution 1:250) (original magnification, 9400).
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Sclerosing epithelioid fibrosarcoma of the upper
extremities had worse distant control compared with SEF
located in the lower extremities with metastasis in six of
seven patients. Gender did not seem to influence (p = 0.069)
local recurrence (13 male and 15 female patients). Followup
was available in 16 of 22 patients who received radiation.
However, in four and seven of 16 cases, resection status
and radiotherapeutic doses were unknown. Twenty-three
patients (34%) died from their disease after a mean of
46 months. Twenty-four (35%) were alive with disease and
20 (31%) were alive without evidence of disease.
Discussion
We systematically reviewed the literature about SEF to
determine its clinical presentation, histopathology, differ-
ential diagnosis, treatment, survival rates, and prognosis.
Although histopathologic appearance of SEF suggests low
grade, it is a high-grade tumor clinically.
The lack of control groups and prospective design, small
sample sizes, and missing treatment details in the reviewed
studies limit our interpretations. Because of incomplete
data, we could not thoroughly assess the influence of sur-
gery evaluated. The small number of patients in distinct
subgroups did not afford adequate power for statistical
analysis.
Sclerosing epithelioid fibrosarcoma, together with FMS
and HSCTGR, belongs to the family of fibrosing fibro-
sarcomas. Fibromyxoid sarcoma initially was described by
Evans [17] in 1987 and characterized as an indolent, low-
grade fibromyxoid neoplasm arising in deep soft tissue
with paradoxical aggressive features. Hyalinizing spindle
cell tumor with giant rosettes is a similarly rare low-grade
fibrosarcoma variant with a very low metastatic potential.
In FMS, the local failure rate was 33%, metastases
occurred in 42%, and 18% of patients were DOD [18].
Local recurrence rates between 30% and 75% have been
observed in several small series with followups ranging
from 74% [38] to 100% [7]. In contrast, recurrence of
metastasis ranged from 0% [39] to 58% [26]. Died of
disease rates ranged from 14% and 33% [16]. Hyalinizing
spindle cell tumor with giant rosettes was described for the
first time by Lane et al. in 1997 [34], who reported one
local recurrence and no metastases in 12 of 19 patients
with available followup. So far, six patients with
pulmonary metastases have been described [11, 19, 20, 35,
38, 45].
Hyalinizing spindle cell tumors with giant rosettes and
FMS have histologic low-grade tumor features and
HSCTGR often manifests by an indolent clinical behavior.
Based on a series of 56 patients with a mean followup of
3 years, local failure occurred in five (9%) and metastatic
disease in three patients (6%; one HSCTGR, two FMS, but
no metastases at diagnosis). One patient was DOD (2%).
These data support the hypothesis that FMS and HSCTGR
may represent the same entity and should be regarded as low-
grade sarcomas [20]. In contrast to HSCTGR and FMS, local
recurrence in patients with SEF was seen in 40% and distant
disease in 80%, and 67% of patients with local recurrence
had distant metastasis develop. Thus, SEF bears malignant
potential and therefore appears as the most malignant variant
in this family of low-grade fibrosarcomas [20, 21, 34, 42, 43]
followed by FMS. This should be taken into consideration
when the decision is made on a treatment plan.
Diagnostically, the most challenging problem is to dis-
tinguish SEF from undifferentiated carcinoma, which
might be impossible based purely on histology. Therefore,
immunohistochemical analysis appears mandatory. Spe-
cific protein expression or genetic changes have not been
described in SEF. The only immunostaining marker con-
sistently reported positive (as in our patient) was vimentin,
which is a general marker for soft tissue sarcomas and
therefore not specific for SEF [1, 3, 4, 6, 7, 9, 10, 13, 18,
29–32, 36, 40, 43]. Occasional positivity of rare tumor cells
for other general markers of soft tissue sarcomas like EMA,
S100, or cytokeratin are not useful for diagnosis of a
patient with SEF, because these also may be positive in
other tumors.
Sclerosing epithelioid fibrosarcoma is a clinically
aggressive but histologically low-grade sarcoma with
unsatisfactory treatment results. It typically takes
33 months from the first onset of symptoms to diagnosis.
Sclerosing epithelioid fibrosarcoma can occur from ado-
lescence to the older years and is localized mainly in soft
tissues, but it also can arise as a primary tumor of bone, in
the neural system, or in the ovary [40]. Sclerosing epithe-
lioid fibrosarcoma has a predisposition for local recurrence
with metastasis primarily to the lung. The role of systemic
treatment remains unclear. Consequently, SEF may be
treated preferably by resection, including reexcision after
intralesional excision. Moreover, preoperative or postop-
erative radiation as used in other soft tissue sarcomas also
should be considered.
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